Prudential Financial’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.53M | Sell |
142,504
-222,320
| -61% | -$5.3M | ﹤0.01% | 1074 |
|
|
2025
Q4 | $8.51M | Sell |
364,824
-37,970
| -9% | -$846K | 0.01% | 683 |
|
|
2025
Q3 | $7.94M | Buy |
402,794
+26,410
| +7% | +$543K | 0.01% | 720 |
|
|
2025
Q2 | $8.17M | Sell |
376,384
-4,800
| -1% | -$113K | 0.01% | 711 |
|
|
2025
Q1 | $9.24M | Sell |
381,184
-172,240
| -31% | -$3.88M | 0.01% | 616 |
|
|
2024
Q4 | $11.5M | Buy |
553,424
+128,525
| +30% | +$2.76M | 0.02% | 551 |
|
|
2024
Q3 | $8.45M | Buy |
424,899
+229,840
| +118% | +$4.26M | 0.01% | 749 |
|
|
2024
Q2 | $3.02M | Sell |
195,059
-32,630
| -14% | -$508K | ﹤0.01% | 1169 |
|
|
2024
Q1 | $3.63M | Buy |
227,689
+9,359
| +4% | +$141K | 0.01% | 1112 |
|
|
2023
Q4 | $3.67M | Sell |
218,330
-357,110
| -62% | -$4.88M | 0.01% | 1099 |
|
|
2023
Q3 | $6.73M | Sell |
575,440
-131,764
| -19% | -$1.76M | 0.01% | 785 |
|
|
2023
Q2 | $9.5M | Sell |
707,204
-37,405
| -5% | -$538K | 0.01% | 669 |
|
|
2023
Q1 | $12.3M | Sell |
744,609
-72,281
| -9% | -$1.19M | 0.02% | 582 |
|
|
2022
Q4 | $15.2M | Sell |
816,890
-675,735
| -45% | -$10.4M | 0.03% | 497 |
|
|
2022
Q3 | $19.1M | Buy |
1,492,625
+209,580
| +16% | +$2.48M | 0.03% | 454 |
|
|
2022
Q2 | $8.99M | Sell |
1,283,045
-144,400
| -10% | -$1.06M | 0.01% | 703 |
|
|
2022
Q1 | $11.8M | Buy |
1,427,445
+174,245
| +14% | +$1.23M | 0.02% | 672 |
|
|
2021
Q4 | $8.48M | Sell |
1,253,200
-402,552
| -24% | -$2.65M | 0.01% | 773 |
|
|
2021
Q3 | $8.78M | Sell |
1,655,752
-273,734
| -14% | -$1.5M | 0.01% | 770 |
|
|
2021
Q2 | $11.1M | Sell |
1,929,486
-819,693
| -30% | -$4.23M | 0.02% | 727 |
|
|
2021
Q1 | $12.7M | Buy |
2,749,179
+77,842
| +3% | +$309K | 0.02% | 668 |
|
|
2020
Q4 | $8.92M | Buy |
2,671,337
+223,500
| +9% | +$751K | 0.02% | 788 |
|
|
2020
Q3 | $7.27M | Buy |
2,447,837
+1,026,088
| +72% | +$4.01M | 0.01% | 795 |
|
|
2020
Q2 | $6.57M | Buy |
1,421,749
+392,281
| +38% | +$1.76M | 0.01% | 857 |
|
|
2020
Q1 | $3.96M | Sell |
1,029,468
-741,815
| -42% | -$3.04M | 0.01% | 1012 |
|
|
2019
Q4 | $6.64M | Buy |
1,771,283
+716,807
| +68% | +$3.35M | 0.01% | 1007 |
|
|
2019
Q3 | $5.6M | Buy |
1,054,476
+621,547
| +144% | +$3.31M | 0.01% | 1062 |
|
|
2019
Q2 | $1.66M | Buy |
432,929
+334,185
| +338% | +$1.44M | ﹤0.01% | 1680 |
|
|
2019
Q1 | $503K | Sell |
98,744
-41,134
| -29% | -$121K | ﹤0.01% | 2083 |
|
|
2018
Q4 | $268K | Sell |
139,878
-80,525
| -37% | -$231K | ﹤0.01% | 2159 |
|
|
2018
Q3 | $833K | Sell |
220,403
-87,467
| -28% | -$274K | ﹤0.01% | 1920 |
|
|
2018
Q2 | $960K | Buy |
307,870
+134,200
| +77% | +$407K | ﹤0.01% | 1914 |
|
|
2018
Q1 | $415K | Buy |
173,670
+53,500
| +45% | +$178K | ﹤0.01% | 2060 |
|
|
2017
Q4 | $469K | Buy |
+120,170
| New | +$397K | ﹤0.01% | 2034 |
|
Other funds holding CPRX
VCM
DM
VPM
Prudential Financial's CPRX Position: Q1 2026 in Review
Prudential Financial reduced its Catalyst Pharmaceutical (CPRX) stake by 61% in Q1 2026, selling an estimated $5.3M and leaving 142,504 shares worth $3.53M. The position accounts for ﹤0.01% of the portfolio, ranked #1074.
Prudential Financial first reported a position in CPRX in Q4 2017 and has held it in 34 quarters since. The position peaked at $19.1M in Q3 2022. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.
- Prudential Financial held 142,504 shares of Catalyst Pharmaceutical worth $3.53M as of Q1 2026.
- Prudential Financial sold 222,320 Catalyst Pharmaceutical shares in Q1 2026, an estimated $5.3M.
- Catalyst Pharmaceutical made up ﹤0.01% of Prudential Financial's portfolio in Q1 2026, its #1074 holding.
- Prudential Financial first reported a position in Catalyst Pharmaceutical in Q4 2017 and has held it in 34 quarters since.
- Prudential Financial's Catalyst Pharmaceutical position peaked at $19.1M in Q3 2022.
- 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.
Based on Prudential Financial's 13F filing for Q1 2026, filed 13 May 2026.